{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04778137",
      "orgStudyIdInfo": {
        "id": "CMAB007-001"
      },
      "organization": {
        "fullName": "Taizhou Mabtech Pharmaceutical Co.,Ltd",
        "class": "INDUSTRY"
      },
      "briefTitle": "The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety",
      "officialTitle": "The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety"
    },
    "statusModule": {
      "statusVerifiedDate": "2021-01",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2020-12-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2021-04-26",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2021-05-25",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2021-02-26",
      "studyFirstSubmitQcDate": "2021-02-26",
      "studyFirstPostDateStruct": {
        "date": "2021-03-02",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2021-10-08",
      "lastUpdatePostDateStruct": {
        "date": "2021-10-11",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Taizhou Mabtech Pharmaceutical Co.,Ltd",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, pharmacodynamics and safety of two formulations of Omalizumab (CMAB007 and Xolair) in healthy subjects."
    },
    "conditionsModule": {
      "conditions": [
        "Asthma"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "OTHER",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 114,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "CMAB007",
          "type": "EXPERIMENTAL",
          "description": "75mg×2",
          "interventionNames": [
            "Drug: Omalizumab"
          ]
        },
        {
          "label": "Xolair",
          "type": "ACTIVE_COMPARATOR",
          "description": "150mg",
          "interventionNames": [
            "Drug: Omalizumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Omalizumab",
          "description": "Biological: CMAB007 Biological: Xolair",
          "armGroupLabels": [
            "CMAB007",
            "Xolair"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Pharmacokinetic Outcome Measures [AUC0-inf]",
          "description": "Area Under the Concentration-time Curve from Time zero to infinity (AUC0-inf) of CMAB007 and Xolair in healthy subjects.",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [Cmax]",
          "description": "Maximum serum concentration (Cmax) of CMAB007 and Xolair in healthy subjects.",
          "timeFrame": "up to day 106"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Pharmacokinetic Outcome Measures [Tmax]",
          "description": "Time to Cmax (Tmax) of CMAB007 and Xolair in healthy subjects",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [t1/2]",
          "description": "Terminal half-life (t1/2) of CMAB007 and Xolair in healthy subjects",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [λz]",
          "description": "Terminal elimination rate constant (λz) of CMAB007 and Xolair in healthy subjects",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [Apparent total body clearance (CL/F)]",
          "description": "Apparent total body clearance (CL/F) of CMAB007 and Xolair in healthy subjects",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Pharmacodynamics [IgE levels]",
          "description": "Free IgE and total IgE levels (the sum of free and omalizumab-bound IgE) in the serum samples from subjects",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Incidence of Treatment-Emergent Adverse Events [Safety]",
          "description": "Treatment-Emergent Adverse Events (TEAEs) of CMAB007 and Xolair in healthy subjects",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [AUC0-t]",
          "description": "Area Under the concentration-time Curve from time zero to the last quantifiable concentration (AUC0-t) of CMAB007 and Xolair in healthy subjects.",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Pharmacokinetic Outcome Measures [Vd/F]",
          "description": "Apparent total distribution (Cd/F) of CMAB007 and Xolair in healthy subjects",
          "timeFrame": "up to day 106"
        },
        {
          "measure": "Immunogenicity",
          "description": "the Immunogenicity of CMAB007 and Xolair in healthy subjects.",
          "timeFrame": "up to day 106"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy subject between the ages of 18 and 45 years.\n* Subject with a body weight of ≥50 kg and ≤ 75kg and a BMI between 19.0\\~26.0 kg/m2 (both inclusive).\n\nExclusion Criteria:\n\n* subject has a medical history and/or current presence of disease\n* subject has undergone surgery within three months before signing the informed consent;\n* Alcoholics or regular drinkers within 3 months before the test, i.e. those who drink more than 14 unites of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits with 40% alcohol), or whose alcohol breath test is positive;\n* Those who have used soft drugs within 3 months prior to signing the informed consent or hard drugs within 1 year prior the trial; those who have positive drug abuse test results;\n* Those who smoke more than 10 cigarettes per day on average in the 6 months before signing the informed consent; or those who have positive nocotine results;\n* Those who have a history of drug or food allergy, or who have special allergy history (asthma, urticaria, etc.); those who have allergic rhinitis, or are known to be allergic to any component of the test drug or latex (contained in the syringe needle cover);\n* Those who drinking too much tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250 ml) every day;\n* Those who have received any drug treatment (including prescription drugs, over-the-counter drugs, biological products, Traditional Chinese medicine, etc.) and health care products within 4 weeks befor signing the informed consent;\n* Those who have a blood donation over 400 ml within 3 months, or 200 ml within 1 month before signing the informed consent, or plan to donate blood during the trail;\n* Those who accept any biological drugs within 3 months, or anti-IgE biological drugs within 12 months before signing the informed consent;\n* Those who plan to donate sperm within 6 months after the administration of the test drug;\n* Participants in other clinical trails within 3 months before signing the informed consent;\n* Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponerma pallidum antibody is positive;\n* The results of medical examination (ECG, X-ray, B-ultrasonic, physical and laboratory examination) are clinical significant abnormalities according to the judgment of the researcher;\n* Anti-nuclear antibody or fecal parasite test is positive;\n* Those who have undergone surgery within 1 months before signing the informed consent, or plan to undergo surgery during the trail period;",
      "healthyVolunteers": true,
      "sex": "MALE",
      "minimumAge": "18 Years",
      "maximumAge": "45 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Shanghai Xuhui Central Hospital",
          "city": "Shanghai",
          "state": "Shanghai Municipality",
          "zip": "200031",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D001249",
          "term": "Asthma"
        }
      ],
      "ancestors": [
        {
          "id": "D001982",
          "term": "Bronchial Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D008173",
          "term": "Lung Diseases, Obstructive"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000069444",
          "term": "Omalizumab"
        }
      ],
      "ancestors": [
        {
          "id": "D000888",
          "term": "Antibodies, Anti-Idiotypic"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": false
}